Regardless of company size, stage or therapeutic area, a strategic evidence-generation plan is essential to pharmaceutical companies throughout the drug development cycle; from identifying strong clinical endpoints to designing studies that promote patient engagement. There are many opportunities for failure along this path, including a lack of a thoughtfully planned and integrated study pipeline or poorly designed studies that don’t meet the evidence requirements demanded by the FDA, investors, payers and other stakeholders. These can be costly and can result in significant long-term impacts on a product’s evidence portfolio, regulatory approval, adoption rate and reimbursement opportunities.
Join Baker Tilly for an informative webinar where our team of life sciences professionals will discuss the framework for how to develop effective evidence-generation strategies that address gaps in your organization's current research portfolio. In addition to understanding this framework, we will discuss how to understand knowledge gaps, identify opportunities for collaboration, and discover thoughtful questions to raise about your organization's own evidence-generation strategy.
There are no prerequisites for this webinar, and advance preparation is not required. There is no cost to attend this webinar.
A certificate of completion will be emailed to you four to six weeks after the event.
CPE credit: One (1) hour total credit
Field of study: Specialized Knowledge (SK)
For more information regarding administrative policies such as complaint and refund policies, please email [email protected].
Baker Tilly is registered with the National Association of State Boards of Accountancy as a sponsor of continuing professional education on the National Registry of CPE Sponsors. State boards of accountancy have final authority on the acceptance of individual courses for CPE credit. Complaints regarding registered sponsors may be submitted to the National Registry of CPE Sponsors through its website: nasbaregistry.org.